News

Public · Published

Freedom Broker downgrades Amgen to Hold from Buy, raises price target to $470 from $450

Freedom Broker downgraded Amgen from Buy to Hold and raised its price target from $450 to $470, a 4.4% increase. The new target implies 2.1% upside from Amgen's Nov. 6 closing price of $460.42.

Published:

Updated:

What happened

Freedom Broker downgraded Amgen from Buy to Hold and raised its price target from $450 to $470, a 4.4% increase. The new target implies 2.1% upside from Amgen’s Nov. 6 closing price of $460.42.

Confirmed

Global impact / market context

The downgrade signals less confidence in Amgen’s shares even as the higher target suggests modest potential upside from the cited close. A Hold rating may temper investor expectations, while the small implied gain offers limited evidence of a strong near-term share-price catalyst.

Analyst inference

Analyst targets for Amgen in the article range from $435 to $530, while Freedom Broker’s $470 target is near the lower end. Such differences can shape investor expectations for the stock, but the article reports no company operating changes or market response.

Analyst inference

What to watch

  1. Watch for later analyst rating or target changes, especially if they differ from Freedom Broker’s $470 target or the $435–$530 range in the cited recent notes. Analyst inference
  2. Compare future targets with Amgen’s share price and the stated 2.1% implied upside; that comparison shows whether the target’s limited potential gain changes. Analyst inference
  3. The article reports no company operating results, forecast changes, or other business developments, so it does not establish a reason for Freedom Broker’s rating change. Confirmed

Evidence

  • Original source link unavailable